To evaluate the effectiveness of treatment CSII therapy for patients with diabetes mellitus of different age groups with long-term follow-up in real clinical practice.
The total group included 239 children and adolescents with T1D on CSII for 3 years and more, including 126 (53) females and 113 (47%) males. The mean age of children was 12.8±3.5 (range from 4.5 to 18.0 years), 65% of whom were adolescents. To assess the effectiveness of treatment on HbA1c level, the total group was provisionally divided into subgroups by age: 4.5-7 years, 8-11 years, 12-18 years.
The target HbA1c level (<7.5%) was found in 67% of children from 4.5-7 year age group, in 55% from 8-12 year age group, and in 35% from 12-18 year age group (p<0.001).
The specific group that requires attention and stricter metabolic control during the use of the insulin pump consists of adolescents older than 12 years. The essential requirement for success of the therapy is a high level of patient compliance.
In the group of adolescents (12-18 years) only 35% of patients had their HbA1c within the target. Poorer glycemic control in adolescence may be related to changes in endocrine regulation, typical to this age, as well as to psychological and social factors and the desire to become independent and free from parents.